Non steroidal anti-inflammatory drugs and inflammatory bowel disease

Pharmaceuticals

Volumn 3, Issue 4, 2010, Pages 1084-1092

  Klein, Amir ^a   Eliakim, Rami ^a  

^a Rambam Health Care Campus ^*  (Israel)

Author keywords

Crohn's; IBD; NSAIDs; Ulcerative colitis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ABDOMINAL PAIN; ARTHRALGIA; ARTHRITIS; CHRONIC DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; ENVIRONMENTAL FACTOR; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HEARTBURN; HEMATOCHEZIA; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; NONHUMAN; PATHOGENESIS; RECURRENT DISEASE; REVIEW; SMOKING;

EID: 77952119310     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3041084     Document Type: Review

References (36)

1. Fordtman, S.A. Gastrointestinal and Liver diseases, 8th ed.; Saunders Elsevier: Philadelphia PA, USA, 2006; pp. 2459-2549.
2. Loftus, E.V., Jr. Inflammatory Bowel Disease extending Its Reach. Gastroenterology 2005, 129, 1117-1120.
3. Podolsky, D.K. Inflammatory Bowel Disease. N. Engl. J. Med. 2002, 347, 417-429.
4. Kefalakes, H.; Stylianides, T.J.; Amanakis, G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009, 65, 963-970.
5. Maiden, L.; Thjodleifsson, B.; Theodors, A.; Gonsales, J.; Bjarnason, I. A quantitative analysis of NSAIDS-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128, 1172-1178.
6. Cryer, B. NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am. J. Gastroenterol. 2005, 100, 1694-1695.
7. Wolfe, M.M.; Lichtenstein, D.R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999, 340, 1888-1899.
8. Bjarnason, I.; Hayllar, J.; Macpherson, A.J.; Russell A.S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104, 1832-1847.
9. Kurahara, K.; Matsumoto, T.; Lida, M.; Honda, K.; Yao, T.; Fujishima, M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am. J. Gastroenterol. 2001, 96, 473-480.
10. Laine L.; Smith, R.; Min, K.; Chen, C.; Dubois, R.W. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther. 2006, 24, 751-767.
11. Guslandi, M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J. Gastroenterol. 2006, 12, 1509-1510.
12. Wallace, J.L. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin. North Am.2001, 30, 971-980.
13. Redfern, J.S.; Feldman, M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989, 96, (Suppl) 596-605.
14. Tanaka, K.; Suemasu, S.; Ishihara, T.; Tasaka, Y.; Arai, Y.; Mizushima, T. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur. J. Pharmacol. 2009, 603, 120-132.
15. Takeuchi, K.; Smale, S.; Premchand, P.; Maiden, L.; Sherwood, R.; Thjodleifsson, B.; Bjornsson, E.; Bjarnason, I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol Hepatol, 2006, 4,196-202.
16. Biancone, L.; Tosti, C.; Geremia, A.; Fina, D.; Petruzziello, C.; Emerenziani, S.; Pallone, F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol. Ther. 2004, 19, 755-764.
17. Singer, II; Kawka, D.W.; Schloemann, S.; Tessner, T.; Riehl, T.; Stenson, W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998, 115, 297-306.
18. Hendel, J.; Nielsen, O.H. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am. J. Gastroenterol. 1997, 92, 1170-1173.
19. Tsubouchi, R.; Hayashi, S.; Aoi, Y.; Nishio, H.; Terashima, S.; Kato, S.; Takeuchi, K. Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. Digestion 2006, 74, 91-100.
20. Cipolla, G.; Crema, F.; Sacco, S.; Moro, E.; De Ponti, F.; Frigi, G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol. Res. 2002, 46, 1-6.
21. Fries, J.F.; Miller, S.R.; Spitz, P.W.; Williams, C.A.; Hubert, H.B.; Bloch, D.A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989, 96(Suppl.), 647-655.
22. Bonner, G.F. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am. J. Gastroenterol. 2001, 96, 1306-1308.
23. Singh, S.; Graff, L.A.; Bernstein, C.N. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am. J. Gastroenterol. 2009, 104, 1298-1313.
24. Meyer, A.M.; Ramzan, N.N.; Heigh, R.I.; Leighton, J.A. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig. Dis. Sci. 2006, 51, 168-172.
25. Felder, J.B.; Korelitz, B.I.; Rajapakse, R.; Schwarz, S.; Horatagis, A.P.; Gleim, G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am. J. Gastroenterol. 2000, 95, 1949-1954.
26. Evans, J.M.; McMahon, A.D.; Murray, F.E.; McDevitt, D.G.; MacDonald, TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40, 619-622.
27. Bonner, G.F.; Walczak, M.; Kitchen, L.; Bayona, M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol 2000, 95, 1946-1948.
28. Bonner, G.F.; Fakhri, A.; Vennamaneni, S.R. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm. Bowel Dis. 2004, 10, 751-757.
29. Mahadevan, U.; Loftus, E.V., Jr.; Tremaine, W.J.; Sandborn, W.J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 2002, 97, 910-914.
30. Sandborn, W.J.; Stenson, WF.; Brynskov, J.; Lorenz, RG.; Steidle, GM.; Robbins, JL.; Kent, JD.; Bloom, BJ.; Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin. Gastroenterol. Hepatol. 2006, 4, 203-211.
31. El-Miedany, Y.; Youssef, S.; Ahmed, I.; El Gaafary, M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 2006, 101, 311-317.
32. Reinisch, W.; Miehsler, W.; Dejaco, C.; Harrer, M.; Waldhoer, T.; Lichtenberger, C.; Vogelsang, H. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol. Ther. 2003, 17, 1371-1380.
33. Wilcox, G.M.; Mattia, A.R. Rofecoxib and inflammatory bowel disease: clinical and pathologic observations. J. Clin. Gastroenterol. 2005, 39, 142-143.
34. Gornet, J.M.; Hassani, Z.; Modigliani, R.; Lemann, M. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib. Am. J. Gastroenterol. 2002, 97, 3209-3210.
35. Miao, X.P.; Ouyang, Q.; Li, H.Y.; Wen, Z.H.; Zhang, D.K.; Cui, X.Y. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Curr. Therap. Res. 2008, 69, 181-191.
36. Takeuchi, A.; Tanaka, A.; Ohno, R.; Yokota, A. Role of COX inhibition in pathogenesis of NSAIDS-induced small intestinal damage. J. Physiol. Pharmacol. 2003, 54 (Suppl.), 165-182.